The money continues to flow for drug development startups that are working on inflammatory and immunology medicines licensed from other companies. A new San Diego

Pfizer has upped the ante in the increasingly competitive market for pneumococcal vaccines with new data on a 25-valent candidate.

Last week at our biopharma and healthcare summit with the Financial Times, I was asked during one of our breaks when we’ll see the first

Pharmaceutical companies’ ability to interact with the patients taking their medications has changed over the last few years. The rise of direct-to-consumer channels, driven largely

💉 Pfizer’s experimental 25-valent pneumococcal shot beats Prevnar 20: The vaccine candidate, codenamed PF-07872412, produced higher geometric mean titers for serotype 3 than Pfizer’s approved